BioProcess Technology Consultants | Special Reports - The Development of Therapeutic Antibody Products Report

THE DEVELOPMENT OF THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS

334 Pages, Published February 2010

A Roadmap for the Development of a Monoclonal antibody ProductS

Monoclonal antibodies are currently the dominant class of biologic products in development, generating much interest and excitement regarding the promise and potential of these biopharmaceutical products. There are many factors that will enable the continued cost-effective development of new antibody products in the coming years, especially the advancements in manufacturing technologies and processes described in this report. This report is intended to provide a roadmap for the development of a monoclonal antibody product from initial discovery through the filing of an Investigational New Drug Application (IND) or Investigational Medicinal Product Dossier (IMPD) or equivalent for first in human clinical trials. The primary focus of the report is on the technical, regulatory, and management issues related to process development, manufacturing, quality control, and analysis of full length single specificity monoclonal antibody products produced in mammalian cell culture. However, much of the discussion is also relevant to the production of antibody-related products such as Fc-fusion proteins and antibody fragments such as single chain antibodies or Fab fragments as well as to antibody-related products produced in non-mammalian host cell lines.

Following the general introduction to monoclonal antibody products contained in Chapter 1, each chapter in the report describes the required or recommended activities needed for the development of a monoclonal antibody product along with potential risks and alternative approaches.

Read an excerpt of Chapter 1

Chapter 2 summarizes the many different approaches and technologies currently available for the discovery of monoclonal antibody products. These discovery technologies result in monoclonal antibody product candidates with optimized target binding affinity, specificity, and activation of other immune system functions, as well as properties that may enhance manufacturability or stability of the final product. Each of the different approaches to monoclonal antibody product discovery discussed in the chapter may result in slightly different monoclonal antibody products with different properties, such as binding to the antibody target, antibody format and post-translational modifications (especially glycosylation), or manufacturability, so that careful selection of the right technology and product are essential in developing the optimal monoclonal antibody product for each therapeutic indication.

Read an excerpt of Chapter 2

The overall goal of a monoclonal antibody development program is to develop a reliable, robust, and reproducible process to manufacture a monoclonal antibody product that is safe to administer to humans. The intricacies of a monoclonal antibody development program, including a summary of all chemistry, manufacturing, and control (CMC) related activities and the associated costs and timing for these activities, are described in Chapter 3. This chapter also discusses the various approaches to product development and the risks associated with accelerating various activities in advancing a monoclonal antibody product from discovery to first-in-human clinical trials.

Read an excerpt of Chapter 3

Any monoclonal antibody development program requires a tremendous amount of analytical information to support the product development efforts from discovery through process development, clinical trials, and commercialization. Chapter 4 describes the numerous methods used to analyze and characterize monoclonal antibody products, including a discussion of the regulatory requirements for these methods. Specific methods required for early stage analysis and characterization of monoclonal antibody products and the rationale for each method are also summarized in this chapter.

Read an excerpt of Chapter 4

Chapter 5 describes the many technologies and approaches available for the generation of suitable production cell lines for monoclonal antibody products and discusses the potential advantages of newer, patented technologies to shorten cell line development timelines. In addition, the requirements for final production clone selection and the preparation and characterization of research and GMP cell banks are reviewed.

Read an excerpt of Chapter 5

In Chapter 6 the development and scale-up of cell culture processes for production of monoclonal antibody products are described, including the development and optimization of cell culture media and additives, and the establishment of the optimal bioreactor conditions to maximize antibody production. The scale-up of these cell culture processes from the laboratory to pilot to commercial scales are also discussed and general guidelines and requirements to enable the GMP manufacture of clinical trial materials and product for commercial sale are presented.

Read an excerpt of Chapter 6

In Chapter 7 the development, optimization, and scale-up of downstream processes for the recovery and purification of monoclonal antibody products from the cell culture bioreactor is described. Because of the similarity among monoclonal antibody products, platform purification processes which take advantage of these constant properties, such as the binding of the Fc portion of antibodies to Protein A can be developed which simplify process development and enable rapid purification of antibodies at large scale. The advantages of these platform processes and a discussion of variables and alternatives to such platforms are described along with integration of the downstream process with the upstream cell culture process to optimize the overall manufacturing process.

Read an excerpt of Chapter 7

A discussion of new techniques and technologies for high throughput process development that may decrease the time required to develop clinically-enabling manufacturing processes and establish the ultimate commercial manufacturing process are described in Chapter 8. These rapid development methods include new automated methods for screening hundreds, if not thousands, of process conditions with minimal amounts of sample and state-of-the-art analytical methods to achieve in much shorter times what previously took many months or years to accomplish. The technologies discussed include methods for quickly optimizing cell culture conditions for maximal antibody production and advances in technology that can accelerate purification process development timelines and shorten the time required to move a new monoclonal antibody product from discovery to the clinic.

Read an excerpt of Chapter 8

The critical issues of monoclonal antibody formulation and stability are discussed in Chapter 9. Many monoclonal antibody products are initially formulated as liquids at relatively low concentrations in aqueous buffered solutions. However, the stability of monoclonal antibody products in these simple buffer conditions is often limited, especially if high concentrations are required for efficient patient dosing. The different approaches towards developing high concentration formulations, both liquid and freeze-dried are discussed along with the advantages, costs, and risks associated with changing product formulations during clinical development and the need to develop formulations which maintain product stability throughout the proposed shelf live of the product.

Read an excerpt of Chapter 9

The details of the manufacture of monoclonal antibody final drug products, including preparation of the formulated drug product, aseptic processing, and filling into the intended container/closure system for use in clinical trials is described in Chapter 10.

Read an excerpt of Chapter 10

The regulatory guidelines for comparability of monoclonal antibody products in early development and later are reviewed in Chapter 11. The preparation of suitable comparability protocols to support these changes and the various analytical methods used to determine comparability are discussed in the chapter along with a discussion of the risks associated with implementing early processes that will require changes later in development and the needs for demonstrating comparability following all changes to a monoclonal antibody product manufacturing during development.

Read an excerpt of Chapter 11

Chapter 12 outlines the goals and objectives of process validation and the changing regulatory requirements for validation resulting from the FDA GMP Initiative and new guidance on process validation. Following these new guidelines, elements of process validation should be performed early in the development of a monoclonal antibody product, continue through the scale-up and implementation of the final manufacturing processes, reach a critical milestone with the production of full scale batches of the monoclonal antibody product just prior to submission of a BLA and will continue throughout the commercial life of the product.

Read an excerpt of Chapter 12

The challenges of defining and implementing an appropriate manufacturing strategy, whether it be building internal manufacturing capacity, outsourcing manufacturing to a contract manufacturing organization (CMO), or a strategy that combines aspects of both, and how to choose the best strategy to minimize risks while maintaining flexibility are discussed in Chapter 13. The chapter also provides an overview of the necessary steps to identify, select, and qualify contract manufacturers or design a pilot plant for in-house manufacturing.

Read an excerpt of Chapter 13

The overall importance of manufacturing economics for monoclonal antibody products from initial process development through clinical development and commercialization are discussed in Chapter 14. With the increasing variety of monoclonal antibody products and the numerous potential applications for these products, the economic demands on producers of monoclonal antibody products will increase, forcing monoclonal antibody manufacturers to become more flexible in their process and facility design. Using production processes currently available, bulk monoclonal antibody products can be manufactured at large scale for less than $100 per gram provided that the production facility is fully utilized and that the products are produced at sufficient scale and quantity.